Home | Contact Us | Search | Site Map
About Us Technology Products R&D Partners Investors Media Careers Hidden
Crucell
Recombinant Paramyxovirus



  PER.C6® Technology
  Vaccine Technology
  PER.C6® Technology
  AdVac® Technology
  Virosome Technology
  Recombinant Paramyxovirus
  Description
  Applications
  Hansenula polymorpha
  Partnering Opportunities
  Protein Technology

Key Strengths

  • Recombinant measles vectors (our Paramyxovirus technology) carrying RNA encoding for antigenic proteins of other human pathogens can be manufactured to high titers using production and purification protocols established for classical measles vaccine manufacturing.

 

  • The recombinant measles vaccine on which the vector is based has an excellent safety track record since the measles vaccine has been safely administered to many millions of people in the last decades.

 

  • Recombinant measles vectors induce high and long-lived immune responses against inserted antigens.

 

  • Recombinant measles vectors are attractive to use for poverty-related diseases because they are produced economically.
  E-mail this page   Print this page

    Home  |  Contact Us  |  Search  |  Site Map  |  
MoveNext - Latus © Crucell 2006 | Disclaimer